Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Total Debt (2016 - 2025)

Avalo Therapeutics' Total Debt history spans 11 years, with the latest figure at $370000.0 for Q2 2025.

  • For Q2 2025, Total Debt changed N/A year-over-year to $370000.0; the TTM value through Jun 2025 reached $370000.0, changed N/A, while the annual FY2024 figure was $360000.0, N/A changed from the prior year.
  • Total Debt reached $370000.0 in Q2 2025 per AVTX's latest filing, up from $360000.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $32.8 million in Q4 2021 to a low of $360000.0 in Q4 2024.
  • Average Total Debt over 5 years is $11.6 million, with a median of $12.0 million recorded in 2022.
  • The largest YoY upside for Total Debt was 58.93% in 2022 against a maximum downside of 58.93% in 2022.
  • A 5-year view of Total Debt shows it stood at $32.8 million in 2021, then plummeted by 58.93% to $13.5 million in 2022, then dropped by 22.36% to $10.5 million in 2023, then crashed by 96.56% to $360000.0 in 2024, then grew by 2.78% to $370000.0 in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Total Debt are $370000.0 (Q2 2025), $360000.0 (Q1 2025), and $360000.0 (Q4 2024).